全文获取类型
收费全文 | 212628篇 |
免费 | 50609篇 |
国内免费 | 2541篇 |
专业分类
耳鼻咽喉 | 2086篇 |
儿科学 | 7983篇 |
妇产科学 | 2175篇 |
基础医学 | 32272篇 |
口腔科学 | 7552篇 |
临床医学 | 26527篇 |
内科学 | 50679篇 |
皮肤病学 | 4670篇 |
神经病学 | 20622篇 |
特种医学 | 8988篇 |
外国民族医学 | 9篇 |
外科学 | 22742篇 |
综合类 | 18577篇 |
现状与发展 | 5篇 |
一般理论 | 10篇 |
预防医学 | 17556篇 |
眼科学 | 1716篇 |
药学 | 19900篇 |
173篇 | |
中国医学 | 7243篇 |
肿瘤学 | 14293篇 |
出版年
2024年 | 257篇 |
2023年 | 1545篇 |
2022年 | 2914篇 |
2021年 | 5730篇 |
2020年 | 10131篇 |
2019年 | 14704篇 |
2018年 | 14204篇 |
2017年 | 15353篇 |
2016年 | 14440篇 |
2015年 | 14342篇 |
2014年 | 17689篇 |
2013年 | 18129篇 |
2012年 | 16260篇 |
2011年 | 16569篇 |
2010年 | 13867篇 |
2009年 | 10041篇 |
2008年 | 10544篇 |
2007年 | 9200篇 |
2006年 | 8273篇 |
2005年 | 7725篇 |
2004年 | 6950篇 |
2003年 | 6252篇 |
2002年 | 5718篇 |
2001年 | 4636篇 |
2000年 | 3163篇 |
1999年 | 2017篇 |
1998年 | 1536篇 |
1997年 | 1494篇 |
1996年 | 1277篇 |
1995年 | 1188篇 |
1994年 | 1156篇 |
1993年 | 869篇 |
1992年 | 886篇 |
1991年 | 791篇 |
1990年 | 646篇 |
1989年 | 619篇 |
1988年 | 531篇 |
1987年 | 459篇 |
1986年 | 418篇 |
1985年 | 497篇 |
1984年 | 419篇 |
1983年 | 271篇 |
1982年 | 326篇 |
1981年 | 294篇 |
1980年 | 252篇 |
1979年 | 218篇 |
1978年 | 188篇 |
1977年 | 158篇 |
1976年 | 154篇 |
1975年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
目的:探讨经皮冠状动脉介入(PCI)术后病人的体力活动水平及其影响因素。方法:选择常州市三级甲等综合医院心内科接受PCI治疗的冠心病病人,收集资料,分析PCI术后冠心病病人体力活动动机、体力活动和自我效能现状;冠心病病人自我效能、体力活动动机与体力活动的相关性,并分析影响PCI术后病人体力活动水平的相关危险因素。结果:共发放调查问卷400份,回收400份,有效率为94.75%(379/400);379例冠心病病人术后每周体力活动为(3570.85±314.19)MET-min,以低、中强度为主;冠心病病人术后自我效能总分、体力活动动机总分与体力活动呈正相关(P<0.05);体质指数(BMI)、PCI次数≥2次、年龄、PCI支架数量≥3枚、自我效能、体力活动动机是影响PCI术后冠心病病人体力活动水平的高危因素(OR>1且P<0.05)。结论:PCI术后病人体力活动水平处于较低的水平,PCI次数、BMI、年龄、PCI支架数量、自我效能、体力活动动机是影响PCI术后冠心病病人体力活动水平的高危因素,临床需针对各高危因素制定相应的干预措施,提高病人体力活动水平。 相似文献
3.
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
5.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
6.
7.
《The Medical clinics of North America》2022,106(3):545-555
8.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
9.
10.
《Vaccine》2022,40(18):2525-2527